These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 23913220)

  • 21. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors.
    Denkert C; Budczies J; Kind T; Weichert W; Tablack P; Sehouli J; Niesporek S; Könsgen D; Dietel M; Fiehn O
    Cancer Res; 2006 Nov; 66(22):10795-804. PubMed ID: 17108116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer.
    Nawrocki ST; Kelly KR; Smith PG; Espitia CM; Possemato A; Beausoleil SA; Milhollen M; Blakemore S; Thomas M; Berger A; Carew JS
    Clin Cancer Res; 2013 Jul; 19(13):3577-90. PubMed ID: 23633453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Getting a chemical handle on protein post-translational modification.
    Heal WP; Tate EW
    Org Biomol Chem; 2010 Feb; 8(4):731-8. PubMed ID: 20135026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pathological anatomy and cellular biology of cancers of the ovary].
    Martin PM; Cuisenier J
    Rev Prat; 1997 Jun; 47(11):1187-93. PubMed ID: 9238813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cardiovascular proteomics: challenges and opportunities for cardiologists of the future].
    Banfi C; Brioschi M; Tremoli E
    G Ital Cardiol (Rome); 2013; 14(7-8):495-503. PubMed ID: 23877547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The ovarian cancer-derived secretory/releasing proteome: A repertoire of tumor markers.
    Zhang Y; Xu B; Liu Y; Yao H; Lu N; Li B; Gao J; Guo S; Han N; Qi J; Zhang K; Cheng S; Wang H; Zhang X; Xiao T; Wu L; Gao Y
    Proteomics; 2012 Jun; 12(11):1883-91. PubMed ID: 22623176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proteomic analysis of human ovarian cancer paclitaxel-resistant cell lines.
    Cao L; Li X; Zhang Y; Peng F; Yi H; Xu Y; Li X; Wang Q
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Apr; 35(4):286-94. PubMed ID: 20448348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gossypol induces apoptosis in ovarian cancer cells through oxidative stress.
    Wang J; Jin L; Li X; Deng H; Chen Y; Lian Q; Ge R; Deng H
    Mol Biosyst; 2013 Jun; 9(6):1489-97. PubMed ID: 23532321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genome packaging and expression.
    Crossley M
    Genome Biol; 2002; 3(5):reports4014. PubMed ID: 12049660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteasome inhibition leads to altered signaling in the proteome of cisplatin-resistant human ovarian carcinoma cell line.
    Duraj J; Pastorek M; Vitkovska J; Cholujova D; Gronesova P; Hunakova L; Sedlak J
    Neoplasma; 2013; 60(6):627-34. PubMed ID: 23906297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of ceramide generation and altered sphingolipid composition are associated with drug resistance in human ovarian carcinoma cells.
    Prinetti A; Millimaggi D; D'Ascenzo S; Clarkson M; Bettiga A; Chigorno V; Sonnino S; Pavan A; Dolo V
    Biochem J; 2006 Apr; 395(2):311-8. PubMed ID: 16356169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparative proteomics analysis of differentially expressed metastasis-associated proteins in human ovarian cancer cell lines].
    Su D; Xu SH; Gu LH
    Zhonghua Fu Chan Ke Za Zhi; 2005 Sep; 40(9):619-22. PubMed ID: 16202319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Studying proteolysis within mitochondria.
    Tatsuta T; Langer T
    Methods Mol Biol; 2007; 372():343-60. PubMed ID: 18314738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of anoikis and suppression of human ovarian tumor growth in vivo by down-regulation of Bcl-X(L).
    Frankel A; Rosen K; Filmus J; Kerbel RS
    Cancer Res; 2001 Jun; 61(12):4837-41. PubMed ID: 11406560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD24⁺ ovary cancer cells exhibit an invasive mesenchymal phenotype.
    Kang KS; Choi YP; Gao MQ; Kang S; Kim BG; Lee JH; Kwon MJ; Shin YK; Cho NH
    Biochem Biophys Res Commun; 2013 Mar; 432(2):333-8. PubMed ID: 23396061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The human mitochondrial proteome: oxidative stress, protein modifications and oxidative phosphorylation.
    Gibson BW
    Int J Biochem Cell Biol; 2005 May; 37(5):927-34. PubMed ID: 15743667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SILAC-based proteomic analysis to dissect the "histone modification signature" of human breast cancer cells.
    Cuomo A; Moretti S; Minucci S; Bonaldi T
    Amino Acids; 2011 Jul; 41(2):387-99. PubMed ID: 20617350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers.
    Gortzak-Uzan L; Ignatchenko A; Evangelou AI; Agochiya M; Brown KA; St Onge P; Kireeva I; Schmitt-Ulms G; Brown TJ; Murphy J; Rosen B; Shaw P; Jurisica I; Kislinger T
    J Proteome Res; 2008 Jan; 7(1):339-51. PubMed ID: 18076136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced chemoresistance and tumor sphere formation as a laboratory model for peritoneal micrometastasis in epithelial ovarian cancer.
    Soriţău O; Tomuleasa CI; Páll E; Virág P; Fischer-Fodor E; Foris V; Barbos O; Tatomir C; Kacsó G; Irimie A
    Rom J Morphol Embryol; 2010; 51(2):259-64. PubMed ID: 20495740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beyond the genome and proteome: targeting protein modifications in cancer.
    Markiv A; Rambaruth ND; Dwek MV
    Curr Opin Pharmacol; 2012 Aug; 12(4):408-13. PubMed ID: 22560919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.